Tag: cancer

BowelScreen and Viatel Technology Group partner on EU project to advance AI in cancer screening

BowelScreen, as part of Ireland’s HSE’s National Screening Service, is contributing to a major EU-funded research initiative exploring how artificial intelligence (AI) and microbiome science could shape the future of colorectal cancer screening.

As part of the five-year Microb-AI-ome project, the national screening programme is supporting research efforts through collaboration with technology partner Viatel Technology Group.

The Microb-AI-ome project, funded by Horizon Europe, brings together institutions from five countries to investigate whether AI-driven analysis of gut microbiome data can improve the accuracy of bowel cancer screening. The research aims to reduce unnecessary colonoscopies, enhance early detection, and improve patient outcomes in the future.

Professor Pádraic Mac Mathúna MD FRCPI, Clinical Director, BowelScreen Ireland said: “This research could pave the way for a more accurate and efficient screening process that supports early detection and prevention of bowel cancer and reduces unnecessary colonoscopies, ultimately improving outcomes for screening participants across Europe.”

For the AI to function effectively, it requires access to a broad and diverse dataset from volunteer screening participants. To ensure privacy and compliance, the Microb-AI-ome platform anonymises all sensitive information and retains it within secure cloud databases. To contribute to this international research effort, BowelScreen has facilitated the enrolment of patients by three research hospitals across Ireland, who will provide stool samples for microbiome analysis.

Viatel, leveraging Microsoft Azure technology, has developed the bespoke, cloud-based data-management solution to manage the Irish data repository.

Professor Pádraic Mac Mathúna added: “The platform we have devised with Viatel will allow us to analyse a huge volume of metadata generated from participants’ stool samples to make it interpretable as a signal to say the person is at risk, or is not at risk.”


James Finglas, Managing Director of Viatel Digital Services said: “This is game-changing for the potential use of AI in population-based cancer screening. It analyses millions of data points per patient to identify an individual’s risk of pre-cancer changes or bowel cancer. Consequently, this technology may identify those who need a colonoscopy, creating positive outcomes for patients.”

Security and compliance were paramount in the platform’s development. Fully compliant with Irish legislation and GDPR standards, the system ensures the highest levels of patient confidentiality and data protection.

“Viatel has the experience and expertise to develop what we need. It was really beneficial to have that collaboration between Microsoft and Viatel to be able to generate this platform for us,” Professor Pádraic Mac Mathúna said. 

This initiative highlights the growing role of the AI sector in healthcare innovation, and underscores the importance of strategic AI roadmaps in shaping the future of healthcare delivery.

“This is a tremendous example of how AI can be adopted in a real and meaningful way. A lot of people are talking about AI right now, but we’re immensely proud to be effecting change in our work to get the most out of Microsoft’s AI solutions,” Finglas concluded.

Trinity St James’s Cancer Institute at St James’s Hospital becomes first in Ireland or UK to introduce robot to make chemotherapy drugs

The Trinity St James’s Cancer Institute at St James’s Hospital in Dublin has become the first hospital in the UK or Ireland to introduce a compounding robot to produce cytotoxic chemotherapy drugs for cancer patients. As part of the evolving robotic programme in the hospital, this new initiative has the potential to supply chemotherapy products more efficiently and safely, increasing productivity and leading to a better experience for cancer patients at the hospital.

Chemotherapy is traditionally produced using a highly manual process carried out in pharmacy departments. Overseen by pharmacists and pharmacy technicians, it is physically intensive, involving measurement of doses, reconstitution of commercially sourced drugs and dilution into patient specific doses. Therefore, there is a risk of human error and a need for high levels of quality assurances and verifications. Staff globally often report repetitive strain injuries due to the labour intensity of production, as well as burnout.

The Aseptic Compounding Unit at St James’s Hospital is the busiest in the country, producing 30,000 products annually. With cancer levels rising alongside a growing and ageing population, this demand will rise in coming years. Funds for the new robot were raised by the St James’s Hospital Foundation.

Gail Melanophy, Director of Pharmacy at St James’s Hospital said: “This is a major step forward for our staff and our cancer patients at the hospital. We  aim to produce up to 50% of the oncology/haematology day ward’s chemotherapy needs within weeks of introduction and we hope this will significantly increase when at full capacity, including inpatient needs. This will free up time for our pharmacists to produce other products that the robot does not make and ensure that our valued patients never have to wait for their treatments.”

Aleena Mary James, nurse, Liz Hogan, patient, and Brid Curran, Clinical Nurse Manager.

The first patient received their treatment made by the new robot at the Trinity St James’s Cancer Institute today (11th April) on the hospital campus. Liz Hogan from Ratoath, County Meath is being treated for cervical cancer at the hospital and was infused with a customised dose of the chemotherapy produced by the robot.

She said: “I noticed no difference at all when I received my dose of chemotherapy today at St James’s Hospital – but I am reassured by the wonderful staff here who have told me that the new robot will help to ensure the chemo for all the cancer patients like me will be of very high quality.”

13 of the most commonly used cytotoxic chemotherapy drugs used at St James’s Hospital have been initially selected to be produced by the robot. Trials at the hospital have demonstrated that the advance preparation of the drugs is readily achievable, meaning they are available in the clinics when patients arrive for their sessions.

For the pharmacy staff, the use of the robot protects them from repetitive strain injuries commonly associated with this type of manual process, as well as from exposure to hazardous drugs used in the compounding of chemotherapy. Patients can be assured of the quality of the chemotherapy produced due to the environment in which the robot is housed as well as the flexibility to use the range and scope of products previously produced in the pharmacy. There are also potential cost savings to be realised as the robot can store partially used drugs for use in the production of subsequent doses, thus optimising the use of expensive drugs.

Aisling Nolan, Director of Development at the St James’s Hospital Foundation, said: “I am delighted that the hard work of the Foundation supporters, from patients to families to our own staff, has paid off with the installation and use of this new robot. Cancer care is a core service at St James’s Hospital and this robot will help our cancer patients and the staff who care for them every day.”

The project was made possible due to a highly collaborative multidisciplinary team including pharmacists, technicians, engineers, electricians and ICT staff along with commercial partners to plan, implement and test the technology.

CEO of St James’s Hospital Prof Mary Day said: “The Trinity St James’s Cancer Institute aspires to being a comprehensive cancer centre where patient care, research, clinical trials and cutting edge treatments combine to lead to better patient outcomes and experiences. Being the first hospital in the UK or Ireland to use this new robot to make chemotherapy drugs is another example of how we are constantly striving to find new and better ways to serve our patients and assist our staff.”

Dell Technologies and University of Limerick join forces using AI to advance predictive and diagnostic cancer research

Dell Technologies (NYSE:DELL) has joined forces with the University of Limerick’s Digital Cancer Research Centre to develop an artificial intelligence (AI) platform and digital twin technology to power predictive and diagnostic research in oncology.

The technology can help clinicians provide more effective cancer care for those with B-cell lymphoma from speeding diagnosis to providing enhanced treatment and improving long-term outcomes for patients in Ireland and worldwide.

Dell created an AI platform for the University that delivers high performance computing power to accelerate oncology and precision medicine research. The platform sits within the Digital Cancer Centre’s multicloud ecosystem. It is powered by Dell’s latest storage arrays and Dell PowerEdge servers optimised for AI to produce cancer patient digital twins for better diagnostics.

With the new AI platform, researchers can:

  • Rapidly accelerate biomarker testing for cancer,
  • Gain a better understanding of how to treat patients with B-cell lymphoma, and
  • Develop personalised therapies based on a person’s tumour characteristics.

By using emerging technologies, researchers at the Digital Pathology Unit at the University of Limerick’s Digital Cancer Research Centre can also better understand the pathogenesis of these malignancies and develop novel therapeutic approaches.

The researchers are particularly interested in the possibility that collagen within the tumour ‘microenvironment’ can cause the cancerous cells to spread around the body and to the central nervous system. Having already identified novel ways to block collagen, the research could lead to new treatments to cure patients before the tumour spreads.

Professor of Molecular Pathology at University of Limerick and Director of the Digital Pathology Unit at the Digital Cancer Research Centre Paul Murray said: “Through our partnership with the Dell Technologies team, we will be able to advance our knowledge of how cells go wrong during cancer development and find new ways to diagnose and treat cancer patients. This is the beginning of a very exciting research project for the team here at the University of Limerick’s Digital Cancer Research Centre, and we’re looking forward to accelerating this project with the digital support and insights from the team at Dell Technologies.”

Catherine Doyle, Managing Director of Dell Technologies, Ireland, said: “The new AI-driven platform developed by Dell Technologies will ultimately help researchers and healthcare professionals deliver precision treatments for patients with B-cell lymphoma by understanding how it develops. Through the creation of these digital twins, the University of Limerick and Dell are taking clinical research to a new level. Together, we are harnessing the power of data through new technologies to benefit patients and healthcare professionals globally.”

Details on the University of Limerick’s Digital Cancer Research Centre can be found at https://www.ul.ie/limerick-dcrc.

Stocktaking.ie and DigiTally Launch Fundraiser for Childhood Cancer Charity with Marathon and Steps Challenge

Ireland’s leading stocktaking service Stocktaking.ie, supported by food service software DigiTally, has launched its 2023 fundraiser to support the Cancer Fund for Children, an all-Ireland charity that provides emotional support to children diagnosed with cancer and their families. The fundraiser officially kicked off on Tuesday 18 April with a coffee morning, while on Sunday 23 April, CEO Patrick McDermott ran the London City Marathon in aid of Daisy Lodge Mayo, a short break centre for families.

Last year, Patrick also successfully ran the Chicago City Marathon, raising funds for Daisy Lodge Mayo. This year, the Stocktaking.ie team will support him with their own Steps Challenge to the equivalent of 55 marathons. The steps challenge also commenced on 18 April and will end on 25 May.

Daisy Lodge, in Newcastle Co. Down, is a nurturing and restorative space that provides families with a chance to connect during a difficult time. The charity urgently needs to build a second centre in Mayo, and the funds raised by Stocktaking.ie and DigiTally will contribute to this effort.

In 2022, Stocktaking.ie raised over €4,000 for the Cancer Fund for Children through a local table quiz and the Chicago City Marathon, with an additional €1,300 raised from the coffee morning. The fundraiser will now continue with former Irish rugby captain Rory Best’s walk from Dublin to Cong, which Patrick will assist with, to raise additional awareness for the cause.

Commenting on the fundraiser Patrick said: “We are proud to launch this effort to support the Cancer Fund for Children and contribute to the building of a second Daisy Lodge in Mayo. We hope to raise as much awareness and funds as possible to support families affected by childhood cancer.”

For more information visit www.stocktaking.ie